

28 February 2025
Life Fund

CM Fidelity MoneyBuilder Growth


Fund Aim

The Fund aims to increase the value of your investment over a period of 5 years or more. The Fund will invest at least 70% in equities (and their related securities) of UK companies (those domiciled, incorporated or having significant business in the UK). The Fund may also invest a proportion of its assets in global companies listed in the UK. Please see the Fidelity website for full details

'ESG Metrics'

This document is provided for the purpose of information only. This factsheet is intended for individuals who are familiar with investment terminology. Please contact your financial adviser if you need an explanation of the terms used. This material should not be relied upon as sufficient information to support an investment decision. The portfolio data on this factsheet is updated on a quarterly basis.

Asset Allocation (as at 31/01/2025)



The composition of asset mix and asset allocation may change at any time and exclude cash unless otherwise stated

Information Statement

The fund has merged into Fidelity UK Opportunities Fund on 21st June 2019; the Fund's aim has changed, however risk profile remains the same. We will continue to refer to Fidelity Money Builder Growth in our literature. Please see Fidelity website for full fund aims and objectives - fidelity.co.uk
 Clerical Medical produce Environmental, Social and Governance themed fund metrics. Selected data can be found using the ESG metric link.

Basic Fund Information


Fund Launch Date	13/01/2005
Fund Size	£1.5m
Sector	ABI UK All Companies
ISIN	GB00B04QPK82
MEX ID	CMGIL
SEDOL	B04QPK8
Manager Name	Matthew Siddle
Manager Since	13/01/2005

Top Ten Holdings

(as at 31/01/2025)

UNILEVER PLC	4.9%
EXPERIAN PLC	4.5%
RELX PLC	4.4%
AUTO TRADER GROUP PLC	3.5%
INTERTEK GROUP PLC	3.5%
THE SAGE GROUP PLC	3.5%
WEIR GROUP PLC	3.5%
BUNZL PLC	3.2%
CONVATEC GROUP PLC	3.1%
NATWEST GROUP PLC	3.1%
TOTAL	37.2%

Past Performance



CM Fidelity MoneyBuilder Growth

ABI UK All Companies

Past performance is not a guide to future performance. Investment value and income from it may fall as well as rise, as a result of market and currency movements. You may not get back the amount originally invested.

Discrete Performance

	31/12/2023 - 31/12/2024	31/12/2022 - 31/12/2023	31/12/2021 - 31/12/2022	31/12/2020 - 31/12/2021	31/12/2019 - 31/12/2020
CM Fidelity MoneyBuilder Growth	0.0%	0.2%	-18.4%	16.0%	2.5%
ABI UK All Companies	6.4%	6.5%	-7.7%	13.2%	-7.1%

Information is shown as unavailable if prior to the launch of fund.

Cumulative Performance

	31/01/2025 - 28/02/2025	30/11/2024 - 28/02/2025	29/02/2024 - 28/02/2025	28/02/2022 - 28/02/2025	29/02/2020 - 28/02/2025
CM Fidelity MoneyBuilder Growth	-2.1%	-0.6%	6.8%	-11.2%	10.9%
ABI UK All Companies	0.1%	2.5%	11.8%	15.1%	26.1%
Quartile	4	4	4	4	4

Source: FE fundinfo as at 28/02/2025

Performance figures are in £ Sterling on a single pricing basis, with income (where applicable) reinvested net of UK tax and net of total annual fund charges. These figures do not include any initial charge or other product charge(s) that may be applicable.

Quarterly Fund Manager Review

The fund (W-ACC) returned -3.8% over the quarter and lagged the index, which returned -0.4%. At a sector level, the fund's Financials underweight cost 190 basis points (bps) in Q4, as higher rates drove earnings upgrades for the banks. The fund will generally be underweight financials, as we find fewer companies that meet our quality threshold in this sector. The holdings in Lloyds and NatWest qualify as simple retail banks with sticky customers, in a consolidated market with strong capital positions that can earn mid-teens return on equity through cycle. The Industrials overweight cost 200bps due to the persistence of higher rates, which contributed to continued subdued industrial activity. Although markets are depressed short term, over time we expect a recovery that will benefit our holdings. At a stock level, Genuit and RS Group reported soft results due to ongoing weak construction and industrial activity and a delayed recovery. Experian reported broadly in line results which were met with slight disappointment, as there was hope for revenue acceleration above the +7% reported which was held back by weaker macro in Brazil and high rates in the US constraining credit activity. Sage saw strong Q4 results with accelerating organic revenue growth to c10%, margin progression with a confident outlook for 2025. After a couple of quarters of slowing growth, there was nervousness in the market, which drove the strong move on results. Trustpilot continued to re-rate on confidence in the new management's strategy to shift the business to focus on larger companies which could improve the economics of the business medium term.

Matthew Siddle 31/12/2024

The views, opinions and forecasts expressed in this document are those of the fund management house. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statements of fact, nor should reliance be placed on these views when making investment decisions.

Fund Rating Information

Overall Morningstar Rating -

Morningstar Medalist Rating -

FE fundinfo Crown Rating ★★★★★

The FE fundinfo Crown Rating relates to this fund. However, the Morningstar ratings are based on the underlying fund. These are supplied by the respective independent ratings agencies and are the latest available at the time this factsheet was issued. Past performance is not a reliable indicator of future results.

Other Information

The views, opinions and forecasts expressed in this document are those of the fund manager. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statement of fact, nor should reliance be placed on these views when making investment decisions.

For further information contact your local sales office or phone Customer Services on 0345 030 6243 (Life and Pensions) 0345 300 2244 (OEIC). Details are also available at www.clericalmedical.co.uk

Not all products have access to this fund, please refer to the relevant product literature. Full terms and conditions are available on request from us using the contact details provided. Charges, terms and the selection of funds we make available may change. Information on the general and specific risks associated with investing in this fund is available in the relevant fund guide, or KIID where applicable. All information is sourced from Scottish Widows or the relevant fund management group unless otherwise stated.